Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $116 to $136.
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $116 to $136.